What preoperative assessment and peri‑operative management should be provided for patients undergoing total abdominal hysterectomy with bilateral salpingo‑oophorectomy for ovarian cancer?

Preoperative Assessment and Perioperative Management for TAHBSO in Ovarian Cancer

Before surgery, patients must undergo abdomino-pelvic CT scan, chest X-ray, serum CA125, complete blood count with differential, and biochemistry for renal and hepatic function to properly stage disease and guide surgical planning. 1

Preoperative Assessment

Essential Imaging and Laboratory Studies

• Abdomino-pelvic CT scan is mandatory to assess disease extent, identify sites of metastasis, and determine resectability 1
• Chest X-ray must be obtained to exclude pleural effusions or pulmonary metastases 1
• Serum CA125 provides baseline tumor marker levels for monitoring treatment response and surveillance 1
• Complete blood count with differential identifies anemia, thrombocytosis, or leukocytosis that may require correction 1
• Renal and hepatic function tests are essential for chemotherapy planning and assessing fitness for surgery 1

Pathological Confirmation

• Definitive diagnosis requires surgical specimen, as ovarian cancer cannot be reliably diagnosed preoperatively 1
• Pathological diagnosis must follow WHO classification to identify specific subtypes: serous, mucinous, endometrioid, clear cell, transitional cell, mixed, and undifferentiated carcinomas 1, 2
• Histologic subtype identification is critical because treatment selection differs significantly, particularly for PARP inhibitors in BRCA1/2-mutated or HRD-positive high-grade tumors 2

Surgical Planning Considerations

• Surgery must be performed by an appropriately trained gynecologic oncologist with experience in ovarian cancer management, as this impacts staging accuracy and cytoreduction success 1
• Assess patient's age, performance status, and comorbidities to determine surgical candidacy and extent of cytoreduction 1
• For advanced disease (FIGO IIb-IV), plan for maximal cytoreductive effort with goal of no residual disease 1

Perioperative Management

Surgical Technique Requirements

For advanced disease (FIGO stage IIb-IIIc), surgery must include:

• Total abdominal hysterectomy and bilateral salpingo-oophorectomy 1
• Omentectomy (infracolic) 1
• Staging biopsies from diaphragmatic peritoneum, paracolic gutters, and pelvic peritoneum 1
• Peritoneal washings for cytologic examination 1
• Systematic pelvic and para-aortic lymphadenectomy or sampling 1
• Appendectomy if mucinous histology is present 1, 3

For early-stage disease (FIGO I-IIa), comprehensive surgical staging requires:

• Median laparotomy with thorough abdominal cavity examination 1
• All components listed above for advanced disease 1
• Upfront maximal surgical effort at cytoreduction with goal of no residual disease 1

Critical Surgical Pitfalls to Avoid

• Do not perform laparoscopic approach for suspected ovarian cancer as midline laparotomy remains standard due to increased risk of capsule rupture and inadequate staging 1
• Do not omit lymphadenectomy in high-grade histologies as 60% of apparent early-stage disease will be upstaged after comprehensive surgical staging 1
• Lymphadenectomy may only be omitted in low-grade endometrioid or expansile mucinous carcinoma with radiologically and clinically negative nodes (lymph node metastasis rate <1%) 1
• Do not perform fertility-sparing surgery for stage IIA disease as it represents extension to uterus or fallopian tubes, making uterine preservation oncologically inappropriate 3

Intraoperative Considerations

• Availability of intraoperative frozen section allows appropriate surgical staging without need for second operative procedure 1
• If disease appears confined to ovary, proceed with complete staging including all biopsies and lymph node assessment 1
• FIGO stage I tumors with dense adhesions to pelvic structures should be upstaged and treated as FIGO II tumors due to similar relapse rates 1

Postoperative Planning

• For FIGO stage Ia/b poorly differentiated, densely adherent, clear cell histology and all grades FIGO stage Ic and IIA: adjuvant chemotherapy with carboplatin (AUC 5-7) plus paclitaxel 175 mg/m² every 3 weeks should be considered 1
• For advanced disease (FIGO IIb-IIIc): standard chemotherapy is carboplatin AUC 5-7 plus paclitaxel 175 mg/m²/3h every 3 weeks for six cycles 1
• If initial maximal cytoreduction was not performed, interval debulking surgery should be considered after three cycles of chemotherapy in patients responding or showing stable disease 1

Special Considerations for Specific Histologies

• Clear cell carcinoma is inherently high-grade and represents poor prognostic factor requiring aggressive surgical staging and adjuvant therapy 1, 2
• High-grade serous carcinoma accounts for 70% of epithelial ovarian cancers and requires genetic testing for BRCA1/2 germline mutations to guide PARP inhibitor therapy 2
• Mucinous carcinoma must be distinguished from metastatic gastrointestinal, pancreatic, or cervical primaries and requires appendectomy 1, 3, 2